William C Reinhold

Mr. William C Reinhold


Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2000 in Nature Genetics
Verified
Journal Article
Closed access
USUwe Scherf
Uwe Scherf
DRDouglas T. Ross
Douglas T. Ross
MWMark Waltham
Mark Waltham
LSLawrence H. Smith
Lawrence H. Smith
JLJae K. Lee
Jae K. Lee
JWJohn N. Weinstein
John N. Weinstein

1 April 2003 in Genome Biology
Verified
Journal Article
Open access
BZBarry R Zeeberg
Barry R Zeeberg
WFWeimin Feng
Weimin Feng
GWGeoffrey Wang
Geoffrey Wang
MWMay D Wang
May D Wang
AFAnthony T Fojo
Anthony T Fojo
JWJohn N Weinstein
John N Weinstein
We have developed GoMiner, a program package that organizes lists of 'interesting' genes (for example, under- and overexpressed genes from a microarray experiment) for biological interpretation in the context of the Gene Ontology. GoMiner provides quantitative and statistical output files and two useful visualizations. The first is a tree-like structure analogous to that in the AmiGO browser and the second is a compact, dynamically interactive 'directed acyclic graph'. Genes displayed in GoMiner are linked to major public bioinformatics resources.

15 July 2012 in Cancer Research
Verified
Journal Article
Closed access
PDF file
WRWilliam C Reinhold
William C Reinhold
MSMargot Sunshine
Margot Sunshine
HLHongfang Liu
Hongfang Liu
SVSudhir Varma
Sudhir Varma
KKKurt W. Kohn
Kurt W. Kohn
YPYves Pommier
Yves Pommier
High-throughput and high-content databases are increasingly important resources in molecular medicine, systems biology, and pharmacology. However, the information usually resides in unwieldy databases, limiting ready data analysis and integration. One resource that offers substantial potential for improvement in this regard is the NCI-60 cell line database compiled by the U.S. National Cancer Institute, which has been extensively characterized across numerous genomic and pharmacologic response platforms. In this report, we introduce a CellMiner (http://discover.nci.nih.gov/cellminer/) web application designed to improve the use of this extensive database. CellMiner tools allowed rapid data retrieval of transcripts for 22,379 genes and 360 microRNAs along with activity reports for 20,503 chemical compounds including 102 drugs approved by the U.S. Food and Drug Administration. Converting these differential levels into quantitative patterns across the NCI-60 clarified data organization and cross-comparisons using a novel pattern match tool. Data queries for potential relationships among parameters can be conducted in an iterative manner specific to user interests and expertise. Examples of the in silico discovery process afforded by CellMiner were provided for multidrug resistance analyses and doxorubicin activity; identification of colon-specific genes, microRNAs, and drugs; microRNAs related to the miR-17-92 cluster; and drug identification patterns matched to erlotinib, gefitinib, afatinib, and lapatinib. CellMiner greatly broadens applications of the extensive NCI-60 database for discovery by creating web-based processes that are rapid, flexible, and readily applied by users without bioinformatics expertise. Cancer Res; 72(14); 3499–511. ©2012 AACR.

11 September 2001 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JSJane E. Staunton
Jane E. Staunton
DSDonna K. Slonim
Donna K. Slonim
HCHilary A. Coller
Hilary A. Coller
PTPablo Tamayo
Pablo Tamayo
MAMichael J. Angelo
Michael J. Angelo
TGTodd R. Golub
Todd R. Golub
In an effort to develop a genomics-based approach to the prediction of drug response, we have developed an algorithm for classification of cell line chemosensitivity based on gene expression profiles alone. Using oligonucleotide microarrays, the expression levels of 6,817 genes were measured in a panel of 60 human cancer cell lines (the NCI-60) for which the chemosensitivity profiles of thousands of chemical compounds have been determined. We sought to determine whether the gene expression signatures of untreated cells were sufficient for the prediction of chemosensitivity. Gene expression-based classifiers of sensitivity or resistance for 232 compounds were generated and then evaluated on independent sets of data. The classifiers were designed to be independent of the cells' tissue of origin. The accuracy of chemosensitivity prediction was considerably better than would be expected by chance. Eighty-eight of 232 expression-based classifiers performed accurately (with P < 0.05) on an independent test set, whereas only 12 of the 232 would be expected to do so by chance. These results suggest that at least for a subset of compounds genomic approaches to chemosensitivity prediction are feasible.

1 August 2004 in Cancer Cell
Verified
Journal Article
Closed access
GSGergely Szakacs
Gergely Szakacs
JAJean-Philippe Annereau
Jean-Philippe Annereau
SLSamir Lababidi
Samir Lababidi
USUma Shankavaram
Uma Shankavaram
Angela ArcielloAngela Arciello
Angela Arciello
MGMichael M. Gottesman
Michael M. Gottesman

17 November 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SNSatoshi Nishizuka
Satoshi Nishizuka
LCLu Charboneau
Lu Charboneau
LYLynn Young
Lynn Young
SMSylvia Major
Sylvia Major
WRWilliam C Reinhold
William C Reinhold
JWJohn N. Weinstein
John N. Weinstein
Because most potential molecular markers and targets are proteins, proteomic profiling is expected to yield more direct answers to functional and pharmacological questions than does transcriptional profiling. To aid in such studies, we have developed a protocol for making reverse-phase protein lysate microarrays with larger numbers of spots than previously feasible. Our first application of these arrays was to profiling of the 60 human cancer cell lines (NCI-60) used by the National Cancer Institute to screen compounds for anticancer activity. Each glass slide microarray included 648 lysate spots representing the NCI-60 cell lines plus controls, each at 10 two-fold serial dilutions to provide a wide dynamic range. Mouse monoclonal antibodies and the catalyzed signal amplification system were used for immunoquantitation. The signal levels from the >30,000 data points for our first 52 antibodies were analyzed by usingp-scanand a quantitative dose interpolation method. Clustered image maps revealed biologically interpretable patterns of protein expression. Among the principal early findings from these arrays were two promising pathological markers for distinguishing colon from ovarian adenocarcinomas. When we compared the patterns of protein expression with those we had obtained for the same genes at the mRNA level by using both cDNA and oligonucleotide arrays, a striking regularity appeared: cell-structure-related proteins almost invariably showed a high correlation between mRNA and protein levels across the NCI-60 cell lines, whereas non-cell-structure-related proteins showed poor correlation.